- Vitamin D supplementation, given in 3 different doses to community-dwelling elderly patients (≥70 years), is not associated with any differential effect on bone mineral density (BMD).
Why this matters
- This randomized controlled trial (RCT) attempts to resolve the conflicting literature on the effect of vitamin D supplementation on bone health.
- Single-center, double-blind RCT of 379 elders assigned to 1 of 3 monthly doses of 25-hydroxyvitamin D [25(OH)D] over the course of 12 months: 12,000 IU (low group), 24,000 IU (medium group), or 48,000 IU (high group).
- Osteoporotic patients had not received antiresorptive or anabolic treatment in 3 prior years.
- Primary outcome: change from baseline in total hip BMD, assessed by dual-energy X-ray absorptiometry.
- Funding: Arthritis Research UK; Medical Research Council, UK.
- Mean baseline plasma 25(OH)D level, 40.0±20.1 nmol/L.
- At 12 months, there were between-group differences in mean 25(OH)D level: 55.9, 64.6, or 79.0 nmol/L (high vs low; P<.01 in the low- medium- and high-dose groups respectively.>
- No differences found between groups in change in BMD at total hip or femoral neck: low vs medium group (P=.39; P=.43, respectively) and low- vs high-dose group (P=.08; P=.62, respectively).
- No dose-related adverse events.
- Short follow-up.